Natural products as leads in schistosome drug discovery

Molecules

Volumn 20, Issue 2, 2015, Pages 1872-1903

  Neves, Bruno J ^a   Andrade, Carolina H ^a   Cravo, Pedro V L ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

Chemical scaffolds; Leads; Natural products; Schistosomiasis; Virtual screening

Indexed keywords

ANTISCHISTOSOMAL AGENT; ARACHIDONIC ACID DERIVATIVE; ARTEMISININ DERIVATIVE; BIOLOGICAL PRODUCT; QUINOLINE DERIVATIVE; TERPENE;

ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; SCHISTOSOMA; SCHISTOSOMIASIS;

ANIMALS; ARACHIDONIC ACIDS; ARTEMISININS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS; QUINOLINES; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMICIDES; TERPENES;

EID: 84921653041     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules20021872     Document Type: Review

References (198)

1. Colley, D.G.; Bustinduy, A.L.; Secor, W.E.; King, C.H. Human schistosomiasis. Lancet 2014, 383, 2253-2264.
2. WHO Schistosomiasis. 2014, Fact Sheet. Available online: http://www.who.int/mediacentre/ factsheets/fs115/en (accessed on 10 December 2014).
3. Gryseels, B.; Polman, K.; Clerinx, J.; Kestens, L. Human schistosomiasis. Lancet 2006, 368, 1106-1118.
4. Ross, A.G.P.; Bartley, P.B.; Sleigh, A.C.; Olds, G.R.; Li, Y.; Williams, G.M.; McManus, D.P. Schistosomiasis. N. Engl. J. Med. 2002, 346, 1212-1120.
5. Gönnert, R.; Andrews, P. Praziquantel, a new board-spectrum antischistosomal agent. Z. Parasitenkd. 1977, 52, 129-150.
6. Angelucci, F.; Miele, A.E.; Boumis, G.; Brunori, M.; Dimastrogiovanni, D.; Bellelli, A. Macromolecular bases of antischistosomal therapy. Curr. Top. Med. Chem. 2011, 11, 2012-2028.
7. Huang, Y.; Xu, Y.; Yu, C.; Li, H.; Yin, X.; Wang, T.; Wang, W.; Liang, Y. Effect of praziquantel prolonged administration on granuloma formation around Schistosoma japonicum eggs in lung of sensitized mice. Parasitol. Res. 2011, 109, 1453-1459.
8. Abdel-Hafeez, E.H.; Ahmad, A.K.; Abdulla, A.M.; Aabdel-Wahab, S.; Mosalem, F.A. Therapeutic effect of alpha lipoic acid combined with praziquantel on liver fibrosis induced by Schistosoma mansoni challenged mice. Parasitol. Res. 2012, 111, 577-586.
9. Ismail, M.; Metwally, A.; Farghaly, A.; Bruce, J.; Tao, L.F.; Bennett, J.L. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am. J. Trop. Med. Hyg. 1996, 55, 214-218.
10. Melman, S.D.; Steinauer, M.L.; Cunningham, C.; Kubatko, L.S.; Mwangi, I.N.; Wynn, N.B.; Mutuku, M.W.; Karanja, D.M.S.; Colley, D.G.; Black, C.L.; et al. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl. Trop. Dis. 2009, 3, e504.
11. Fallon, P.G.; Sturrock, R.F.; Niang, A.C.; Doenhoff, M.J. Short report: Diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am. J. Trop. Med. Hyg. 1995, 53, 61-62.
12. Couto, F.F.B.; Coelho, P.M.Z.; Araújo, N.; Kusel, J.R.; Katz, N.; Jannotti-Passos, L.K.; Mattos, A.C.A. Schistosoma mansoni: A method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem. Inst. Oswaldo Cruz 2011, 106, 153-157.
13. Fallon, P.G.; Doenhoff, M.J. Drug-resistant schistosomiasis: Resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am. J. Trop. Med. Hyg. 1994, 51, 83-88.
14. Ismail, M.M.; Taha, S.A.; Farghaly, A.M.; El-Azony, A.S. Laboratory induced resistance to praziquantel in experimental schistosomiasis. J. Egypt. Soc. Parasitol. 1994, 24, 685-695.
15. Schuffenhauer, A.; Varin, T. Rule-Based Classification of Chemical Structures by Scaffold. Mol. Inf. 2011, 47, 646-664.
16. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 2012, 75, 311-335.
17. Harvey, A.L. Natural products in drug discovery. Drug Discov. Today 2008, 13, 894-901.
18. Bohlin, L.; Göransson, U.; Alsmark, C.; Wedén, C.; Backlund, A. Natural products in modern life science. Phytochem. Rev. 2010, 9, 279-301.
19. Harvey, A.L.; Clark, R.L.; Mackay, S.P.; Johnston, B.F. Current strategies for drug discovery through natural products. Expert Opin. Drug Discov. 2010, 5, 559-568.
20. Datry, A.; Thellier, M.; Alfa-Cissé, O.; Danis, M.; Caumes, E. Ivermectin, a broad spectrum antiparasitic drug. Press. Méd. 2002, 31, 607-611.
21. Butler, M.S. The role of natural product chemistry in drug discovery. J. Nat. Prod. 2004, 67, 2141-2153.
22. Guido, R.V.C.; Oliva, G.; Andricopulo, A.D. Modern drug discovery technologies: Opportunities and challenges in lead discovery. Comb. Chem. High Throughput Screen. 2011, 14, 830-839.
23. Baker, D.D.; Chu, M.; Oza, U.; Rajgarhia, V. The value of natural products to future pharmaceutical discovery. Nat. Prod. Rep. 2007, 24, 1225-1244.
24. Ojima, I. Modern natural products chemistry and drug discovery. J. Med. Chem. 2008, 51, 2587-2588.
25. TimTec Natural Products Library. Available online: http://www.timtec.net/natural-compound-library.htm (accessed on 12 December 2014).
26. IBScreen Natural Products. Available online: http://www.ibscreen.com/index.htm (accessed on 10 December 2014).
27. Specs Natural Products. Available online: http://www.specs.net/ (accessed on 10 December 2014).
28. Schuster, D.; Wolber, G. Identification of bioactive natural products by pharmacophore-based virtual screening. Curr. Pharm. Des. 2010, 16, 1666-1681.
29. Geldenhuys, W.J.; Bishayee, A.; Darvesh, A.S.; Carroll, R.T. Natural products of dietary origin as lead compounds in virtual screening and drug design. Curr. Pharm. Biotechnol. 2012, 13, 117-124.
30. Ndjonka, D.; Rapado, L.N.; Silber, A.M.; Liebau, E.; Wrenger, C. Natural products as a source for treating neglected parasitic diseases. Int. J. Mol. Sci. 2013, 14, 3395-3439.
31. Erasmus, D.A. A comparative study of the reproductive system of mature, immature and "unisexual" female Schistosoma mansoni. Parasitology 1973, 67, 165-183.
32. Patocka, N.; Sharma, N.; Rashid, M.; Ribeiro, P. Serotonin signaling in Schistosoma mansoni: A serotonin-activated G protein-coupled receptor controls parasite movement. PLoS Pathog. 2014, 10, e1003878.
33. Ribeiro, P.; Patocka, N. Neurotransmitter transporters in schistosomes: Structure, function and prospects for drug discovery. Parasitol. Int. 2013, 62, 629-638.
34. Han, Z.-G.; Brindley, P.J.; Wang, S.-Y.; Chen, Z. Schistosoma genomics: New perspectives on schistosome biology and host-parasite interaction. Annu. Rev. Genomics Hum. Genet. 2009, 10, 211-240.
35. Van Agtmael, M.A.; Eggelte, T.A.; van Boxtel, C.J. Artemisinin drugs in the treatment of malaria: From medicinal herb to registered medication. Trends Pharmacol. Sci. 1999, 20, 199-205.
36. Ho, W.E.; Peh, H.Y.; Chan, T.K.; Wong, W.S. F. Artemisinins: Pharmacological actions beyond anti-malarial. Pharmacol. Ther. 2014, 142, 126-139.
37. Li, Y. Qinghaosu (artemisinin): Chemistry and pharmacology. Acta Pharmacol. Sin. 2012, 33, 1141-1146.
38. Frezza, T.F.; Fernandes de Oliveira, C.N.; Banin, T.M.; Garcia Rehder, V.L.; Boaventura, S., Jr.; Allegretti, S.M. Tegumentary changes in two different strains of Schistosoma mansoni treated with artemisinin and artesunic acid. Rev. Patol. Trop. 2013, 42, 309-321.
39. Li, H.-J.; Wang, W.; Qu, G.-L.; Tao, Y.-H.; Xing, Y.-T.; Li, Y.-Z.; Wei, J.-Y.; Dai, J.-R.; Liang, Y.-S. In-vivo activity of dihydroartemisinin against Schistosoma japonicum. Ann. Trop. Med. Parasitol. 2011, 105, 181-185.
40. Li, H.; Wang, W.; Qu, G.; Li, Y.; Tao, Y.; Xing, Y.; Wang, X.; Dai, Y.; Wei, J.; Dai, J.; et al. Effect of the in vivo activity of dihydroartemisinin against Schistosoma mansoni infection in mice. Parasitol. Res. 2012, 110, 1727-1732.
41. Chen, D.J.; Fu, L.F.; Shao, P.P.; Wu, F.Z.; Fan, C.Z.; Shu, H.; Ren, C.X.; Sheng, X.L. Experimental studies on antischistosomal activity of qinghaosu. Chin. Med. J. (Engl.) 1980, 60, 4222-4425.
42. Shaohong, L.; Kumagai, T.; Qinghua, A.; Xiaolan, Y.; Ohmae, H.; Yabu, Y.; Siwen, L.; Liyong, W.; Maruyama, H.; Ohta, N. Evaluation of the anthelmintic effects of artesunate against experimental Schistosoma mansoni infection in mice using different treatment protocols. Parasitol. Int. 2006, 55, 63-68.
43. Wang, W.; Li, T.-Y.; Ji, Y.; Qu, G.-L.; Qian, Y.-L.; Li, H.-J.; Dai, J.-R.; Liang, Y.-S. Efficacy of artemether and artesunate in mice infected with praziquantel non-susceptible isolate of Schistosoma japonicum. Parasitol. Res. 2014, 113, 925-931.
44. Jiraungkoorskul, W.; Sahaphong, S.; Sobhon, P.; Riengrojpitak, S.; Kangwanrangsan, N. Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice. Parasitol. Int. 2005, 54, 177-183.
45. Shuhua, X.; Chollet, J.; Weiss, N.; Bergquist, R.N.; Tanner, M. Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol. Int. 2000, 49, 19-24.
46. El-Beshbishi, S.N.; Taman, A.; El-Malky, M.; Azab, M.S.; El-Hawary, A.K.; El-Tantawy, D. In vivo effect of single oral dose of artemether against early juvenile stages of Schistosoma mansoni Egyptian strain. Exp. Parasitol. 2013, 135, 240-245.
47. Shuhua, X.; Utzinger, J.; Chollet, J.; Endriss, Y.; N'Goran, E.K.; Tanner, M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int. J. Parasitol. 2000, 30, 1001-1006.
48. Xiao, S.-H.; Tanner, M.; Shen, B.-G.; Utzinger, J.; Chollet, J. Effect of artemether on the tegument of adult Schistosoma haematobium recovered from mice. Chin. J. Parasitol. Parasit. Dis. 2006, 24, 425-432.
49. Li, H.-J.; Wang, W.; Li, Y.-Z.; Qu, G.-L.; Xing, Y.-T.; Tao, Y.-H.; Wei, J.-Y.; Dai, J.-R.; Liang, Y.-S. Effects of artemether, artesunate and dihydroartemisinin administered orally at multiple doses or combination in treatment of mice infected with Schistosoma japonicum. Parasitol. Res. 2011, 109, 515-519.
50. Xiao, S.-H.; Wu, Y.-L.; Tanner, M.; Wu, W.-M.; Utzinger, J.; Mei, J.-Y.; Scorneaux, B.; Chollet, J.; Zhai, Z. Schistosoma japonicum: In vitro effects of artemether combined with haemin depend on cultivation media and appraisal of artemether products appearing in the media. Parasitol. Res. 2003, 89, 459-466.
51. Xiao, S.; Chollet, J.; Utzinger, J.; Matile, H.; Mei, J.; Tanner, M. Artemether administered together with haemin damages schistosomes in vitro. Trans. R. Soc. Trop. Med. Hyg. 2001, 95, 67-71.
52. Mei, H.; LoVerde, P.T. Schistosoma mansoni: The developmental regulation and immunolocalization of antioxidant enzymes. Exp. Parasitol. 1997, 86, 69-78.
53. Panic, G.; Duthaler, U.; Speich, B.; Keiser, J. Repurposing drugs for the treatment and control of helminth infections. Int. J. Parasitol. 2014, 4, 185-200.
54. Liu, Y.-X.; Wu, W.; Liang, Y.-J.; Jie, Z.-L.; Wang, H.; Wang, W.; Huang, Y.-X. New uses for old drugs: The tale of artemisinin derivatives in the elimination of schistosomiasis japonica in China. Molecules 2014, 19, 15058-15074.
55. N'Goran, E.K.; Utzinger, J.; Gnaka, H.N.; Yapi, A.; N'Guessan, N.A.; Kigbafori, S.D.; Lengeler, C.; Chollet, J.; Shuhua, X.; Tanner, M. Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am. J. Trop. Med. Hyg. 2003, 68, 24-32.
56. Utzinger, J.; N'Goran, E.K.; N'Dri, A.; Lengeler, C.; Xiao, S.; Tanner, M. Oral artemether for prevention of Schistosoma mansoni infection: Randomised controlled trial. Lancet 2000, 355, 1320-1325.
57. Keiser, J.; N'Guessan, N.A.; Adoubryn, K.D.; Silué, K.D.; Vounatsou, P.; Hatz, C.; Utzinger, J.; N'Goran, E.K. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: Randomized, exploratory open-label trial. Clin. Infect. Dis. 2010, 50, 1205-1213.
58. Obonyo, C.O.; Muok, E.M.O.; Mwinzi, P.N.M. Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: An open-label randomised controlled trial. Lancet Infect. Dis. 2010, 10, 603-611.
59. Mohamed, A.A.; Mahgoub, H.M.; Magzoub, M.; Gasim, G.I.; Eldein, W.N.; Ahmed, A.A.A.; Adam, I. Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans. R. Soc. Trop. Med. Hyg. 2009, 103, 1062-1064.
60. Liu, R.; Dong, H.-F.; Guo, Y.; Zhao, Q.-P.; Jiang, M.-S. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: A systematic review and meta-analysis. Parasit. Vectors 2011, 4, 201.
61. Pérez del Villar, L.; Burguillo, F.J.; López-Abán, J.; Muro, A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One 2012, 7, e45867.
62. Ansari, M.T.; Saify, Z.S.; Sultana, N.; Ahmad, I.; Saeed-Ul-Hassan, S.; Tariq, I.; Khanum, M. Malaria and artemisinin derivatives: An updated review. Mini Rev. Med. Chem. 2013, 13, 1879-1902.
63. Ledwitch, K.; Ogburn, R.; Cox, J.; Graham, R.; Fritzsche, A.; Gosnell, D.; Manning, T. Taxol: Efficacy against oral squamous cell carcinoma. Mini Rev. Med. Chem. 2013, 13, 509-521.
64. Huang, M.; Lu, J.-J.; Huang, M.-Q.; Bao, J.-L.; Chen, X.-P.; Wang, Y.-T. Terpenoids: Natural products for cancer therapy. Expert Opin. Investig. Drugs 2012, 21, 1801-1818.
65. De Moraes, J.; Almeida, A.A.C.; Brito, M.R.M.; Marques, T.H.C.; Lima, T.C.; de Sousa, D.P.; Nakano, E.; Mendonça, R.Z.; Freitas, R.M. Anthelmintic activity of the natural compound (+)-limonene epoxide against Schistosoma mansoni . Planta Med. 2013, 79, 253-258.
66. Porto, T.S.; da Silva Filho, A.A.; Magalhães, L.G.; dos Santos, R.A.; Furtado, N.A.J.C.; Arakawa, N.S.; Said, S.; de Oliveira, D.C.R.; Gregório, L.E.; Rodrigues, V.; et al. Fungal transformation and schistosomicidal effects of pimaradienoic acid. Chem. Biodivers. 2012, 9, 1465-1474.
67. Bandeira, S.O.; Gaspar, F.; Pagula, F.P. African ethnobotany and healthcare: Emphasis on mozambique. Pharm. Biol. 2001, 39 (Suppl. S1), 70-73.
68. Ramalhete, C.; Magalhães, L.G.; Rodrigues, V.; Mulhovo, S.; Da Silva Filho, A.A.; Ferreira, M.-J.U. In vitro schistosomicidal activity of balsaminol F and karavilagenin C. Planta Med. 2012, 78, 1912-1917.
69. Ramalhete, C.; Lopes, D.; Molnár, J.; Mulhovo, S.; Rosário, V.E.; Ferreira, M.-J.U. Karavilagenin C derivatives as antimalarials. Bioorg. Med. Chem. 2011, 19, 330-338.
70. Ramalhete, C.; da Cruz, F.P.; Lopes, D.; Mulhovo, S.; Rosário, V.E.; Prudêncio, M.; Ferreira, M.-J.U. Triterpenoids as inhibitors of erythrocytic and liver stages of Plasmodium infections. Bioorg. Med. Chem. 2011, 19, 7474-7481.
71. Johann, S.; Oliveira, F.B.; Siqueira, E.P.; Cisalpino, P.S.; Rosa, C.A.; Alves, T.M.A.; Zani, C.L.; Cota, B.B. Activity of compounds isolated from Baccharis dracunculifolia D.C. (Asteraceae) against Paracoccidioides brasiliensis. Med. Mycol. 2012, 50, 843-851.
72. Silva, M.P.N.; Oliveira, G.L.S.; de Carvalho, R.B.F.; de Sousa, D.P.; Freitas, R.M.; Pinto, P.L.S.; de Moraes, J. Antischistosomal activity of the terpene nerolidol. Molecules 2014, 19, 3793-3803.
73. Barth, L.R.; Fernandes, A.P.M.; Ribeiro-Paes, J.T.; Rodrigues, V. Effects of Goyazensolide during in Vitro Cultivation of Schistosoma mansoni . Mem. Inst. Oswaldo Cruz 1997, 92, 427-429.
74. Jisaka, M.; Kawanaka, M.; Sugiyama, H.; Takegawa, K.; Huffman, M.A.; Ohigashi, H.; Koshimizu, K. Antischistosomal activities of sesquiterpene lactones and steroid glucosides from Vernonia amygdalina, possibly used by wild chimpanzees against parasite-related diseases. Biosci. Biotechnol. Biochem. 1992, 56, 845-846.
75. Berriman, M.; Haas, B.J.; LoVerde, P.T.; Wilson, R.A.; Dillon, G.P.; Cerqueira, G.C.; Mashiyama, S.T.; Al-Lazikani, B.; Andrade, L.F.; Ashton, P.D.; et al . The genome of the blood fluke Schistosoma mansoni. Nature 2009, 460, 352-358.
76. Consortium, F.A. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009, 460, 345-351.
77. Ross, F.; Hernández, P.; Porcal, W.; López, G.V.; Cerecetto, H.; González, M.; Basika, T.; Carmona, C.; Fló, M.; Maggioli, G.; et al. Identification of thioredoxin glutathione reductase inhibitors that kill cestode and trematode parasites. PLoS One 2012, 7, e35033.
78. Beckmann, S.; Leutner, S.; Gouignard, N.; Dissous, C.; Grevelding, C.G. Protein kinases as potential targets for novel anti-schistosomal strategies. Curr. Pharm. Des. 2012, 18, 3579-3594.
79. Ray, D.; Williams, D.L. Characterization of the phytochelatin synthase of Schistosoma mansoni . PLoS Negl. Trop. Dis. 2011, 5, e1168.
80. Ziniel, P.D.; Desai, J.; Cass, C.L.; Gatto, C.; Oldfield, E.; Williams, D.L. Characterization of potential drug targets farnesyl diphosphate synthase and geranylgeranyl diphosphate synthase in Schistosoma mansoni. Antimicrob. Agents Chemother. 2013, 57, 5969-5976.
81. Lancelot, J.; Caby, S.; Dubois-Abdesselem, F.; Vanderstraete, M.; Trolet, J.; Oliveira, G.; Bracher, F.; Jung, M.; Pierce, R.J. Schistosoma mansoni Sirtuins: Characterization and potential as chemotherapeutic targets. PLoS Negl. Trop. Dis. 2013, 7, e2428.
82. Wu, W.; Wang, Y. Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components. Acta Pharmacol. Sin. 2012, 33, 1119-1130.
83. Zhou, L.; Zuo, Z.; Chow, M.S.S. Danshen: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 2005, 45, 1345-1359.
84. Lea, W.A.; Jadhav, A.; Rai, G.; Sayed, A.A.; Cass, C.L.; Inglese, J.; Williams, D.L.; Austin, C.P.; Simeonov, A. A 1,536-well-based kinetic HTS assay for inhibitors of Schistosoma mansoni thioredoxin glutathione reductase. Assay Drug Dev. Technol. 2008, 6, 551-555.
85. Williams, D.L.; Bonilla, M.; Gladyshev, V.N.; Salinas, G. Thioredoxin glutathione reductase-dependent redox networks in platyhelminth parasites. Antioxid. Redox Signal. 2013, 19, 735-745.
86. Kuntz, A.N.; Davioud-Charvet, E.; Sayed, A.A.; Califf, L.L.; Dessolin, J.; Arnér, E.S.J.; Williams, D.L. Thioredoxin glutathione reductase from Schistosoma mansoni: An essential parasite enzyme and a key drug target. PLoS Med. 2007, 4, e206.
87. Bonilla, M.; Denicola, A.; Marino, S.M.; Gladyshev, V.N.; Salinas, G. Linked thioredoxin-glutathione systems in platyhelminth parasites: Alternative pathways for glutathione reduction and deglutathionylation. J. Biol. Chem. 2011, 286, 4959-4967.
88. Veras, L.M.; Guimaraes, M.A.; Campelo, Y.D.; Vieira, M.M.; Nascimento, C.; Lima, D.F.; Vasconcelos, L.; Nakano, E.; Kuckelhaus, S.S.; Batista, M.C.; et al. Activity of epiisopiloturine against Schistosoma mansoni. Curr. Med. Chem. 2012, 19, 2051-2058.
89. De Moraes, J.; Nascimento, C.; Lopes, P.O.M.V.; Nakano, E.; Yamaguchi, L.F.; Kato, M.J.; Kawano, T. Schistosoma mansoni : In vitro schistosomicidal activity of piplartine. Exp. Parasitol. 2011, 127, 357-364.
90. Dos Santos, A.F.; Fonseca, S.A.; César, F.A.; de Azevedo Albuquerque, M.C.P.; Santana, J.V.; Santana, A.E.G. A penta-substituted pyridine alkaloid from the rhizome of Jatropha elliptica (Pohl) Muell. Arg. is active against Schistosoma mansoni and Biomphalaria glabrata. Parasitol. Res. 2014, 113, 1077-1084.
91. Silva-Moraes, V.; Couto, F.F.B.; Vasconcelos, M.M.; Araújo, N.; Coelho, P.M.Z.; Katz, N.; Grenfell, R.F.Q.; Fernanda, F.; Couto, B.; Marcos, P.; et al. Antischistosomal activity of a calcium channel antagonist on schistosomula and adult Schistosoma mansoni worms. Mem. Inst. Oswaldo Cruz 2013, 108, 600-604.
92. Miranda, M.A.; Magalhães, L.G.; Tiossi, R.F.J.; Kuehn, C.C.; Oliveira, L.G.R.; Rodrigues, V.; McChesney, J.D.; Bastos, J.K. Evaluation of the schistosomicidal activity of the steroidal alkaloids from Solanum lycocarpum fruits. Parasitol. Res. 2012, 111, 257-262.
93. Zhang, S.-M.; Coultas, K. Identification of plumbagin and sanguinarine as effective chemotherapeutic agents for treatment of schistosomiasis. Int. J. Parasitol. Drugs Drug Resist. 2013, 3, 28-34.
94. Corrêa Soares, J.B.R.; Menezes, D.; Vannier-Santos, M.A.; Ferreira-Pereira, A.; Almeida, G.T.; Venancio, T.M.; Verjovski-Almeida, S.; Zishiri, V.K.; Kuter, D.; Hunter, R.; et al . Interference with hemozoin formation represents an important mechanism of schistosomicidal action of antimalarial quinoline methanols. PLoS Negl. Trop. Dis. 2009, 3, e477.
95. Oliveira, M.F.; D'Avila, J.C.P.; Torres, C.R.; Oliveira, P.L.; Tempone, A.J.; Rumjanek, F.D.; Braga, C.M.S.; Silva, J.R.; Dansa-Petretski, M.; Oliveira, M.A.; et al. Haemozoin in Schistosoma mansoni . Mol. Biochem. Parasitol. 2000, 111, 217-221.
96. Oliveira, M.F.; Timm, B.L.; Machado, E.A.; Miranda, K.; Attias, M.; Silva, J.R.; Dansa-Petretski, M.; de Oliveira, M.A.; de Souza, W.; Pinhal, N.M.; et al. On the pro-oxidant effects of haemozoin. FEBS Lett. 2002, 512, 139-144.
97. Keiser, J.; Chollet, J.; Xiao, S.-H.; Mei, J.-Y.; Jiao, P.-Y.; Utzinger, J.; Tanner, M. Mefloquine-An aminoalcohol with promising antischistosomal properties in mice. PLoS Negl. Trop. Dis. 2009, 3, e350.
98. Manneck, T.; Haggenmüller, Y.; Keiser, J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 2010, 137, 85-98.
99. Manneck, T.; Braissant, O.; Ellis, W.; Keiser, J. Schistosoma mansoni : Antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp. Parasitol. 2011, 127, 260-269.
100. Ingram, K.; Ellis, W.; Keiser, J. Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob. Agents Chemother. 2012, 56, 3207-3215.
101. Keiser, J.; Manneck, T.; Vargas, M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J. Antimicrob. Chemother. 2011, 66, 1791-1797.
102. Mierziak, J.; Kostyn, K.; Kulma, A. Flavonoids as Important Molecules of Plant Interactions with the Environment. Molecules 2014, 19, 16240-16265.
103. Buer, C.S.; Imin, N.; Djordjevic, M.A. Flavonoids: New roles for old molecules. J. Integr. Plant Biol. 2010, 52, 98-111.
104. Ravishankar, D.; Rajora, A.K.; Greco, F.; Osborn, H.M.I. Flavonoids as prospective compounds for anti-cancer therapy. Int. J. Biochem. Cell Biol. 2013, 45, 2821-2831.
105. Bhullar, K.S.; Rupasinghe, H.P.V. Polyphenols: Multipotent therapeutic agents in neurodegenerative diseases. Oxid. Med. Cell. Longev. 2013, 2013, doi:10.1155/2013/891748.
106. Van Dam, R.M.; Naidoo, N.; Landberg, R. Dietary flavonoids and the development of type 2 diabetes and cardiovascular diseases: Review of recent findings. Curr. Opin. Lipidol. 2013, 24, 25-33.
107. Lyddiard, J.R.A.; Whitfield, P.J.; Bartlett, A. Antischistosomal bioactivity of isoflavonoids from Millettia thonningii (Leguminosae). J. Parasitol. 2002, 88, 163-170.
108. Cunha, N.L.; Uchôa, C.J.D.M.; Cintra, L.S.; de Souza, H.C.; Peixoto, J.A.; Silva, C.P.; Magalhães, L.G.; Gimenez, V.M.M.; Groppo, M.; Rodrigues, V.; et al. In vitro schistosomicidal activity of some brazilian cerrado species and their isolated compounds. Evid. Based. Complement. Altern. Med. 2012, 2012, 173614.
109. Braguine, C.G.; Bertanha, C.S.; Gonçalves, U.O.; Magalhães, L.G.; Rodrigues, V.; Melleiro Gimenez, V.M.; Groppo, M.; Silva, M.L.A.E.; Cunha, W.R.; Januário, A.H.; et al. Schistosomicidal evaluation of flavonoids from two species of Styrax against Schistosoma mansoni adult worms. Pharm. Biol. 2012, 50, 925-929.
110. Kuhn, I.; Kellenberger, E.; Said-Hassane, F.; Villa, P.; Rognan, D.; Lobstein, A.; Haiech, J.; Hibert, M.; Schuber, F.; Muller-Steffner, H. Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme. Bioorg. Med. Chem. 2010, 18, 7900-7910.
111. You, J.-Y.; Peng, C.; Liu, X.; Ji, X.-J.; Lu, J.; Tong, Q.; Wei, P.; Cong, L.; Li, Z.; Huang, H. Enzymatic hydrolysis and extraction of arachidonic acid rich lipids from Mortierella alpina. Bioresour. Technol. 2011, 102, 6088-6094.
112. Liu, X.; Ji, X.; Zhang, H.; Fu, N.; Yan, L.; Deng, Z.; Huang, H. Development of a defined medium for arachidonic acid production by Mortierella alpina using a visualization method. Appl. Biochem. Biotechnol. 2012, 168, 1516-527.
113. Ji, X.-J.; Ren, L.-J.; Nie, Z.-K.; Huang, H.; Ouyang, P.-K. Fungal arachidonic acid-rich oil: Research, development and industrialization. Crit. Rev. Biotechnol. 2014, 34, 197-214.
114. El Ridi, R.; Aboueldahab, M.; Tallima, H.; Salah, M.; Mahana, N.; Fawzi, S.; Mohamed, S.H.; Fahmy, O.M. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium . Antimicrob. Agents Chemother. 2010, 54, 3383-3389.
115. Tallima, H.; Salah, M.; El-Ridi, R. In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae. J. Parasitol. 2005, 91, 1094-1102.
116. El Ridi, R.; Tallima, H. Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface. J. Parasitol. 2006, 92, 730-737.
117. ClinicalTrials. Arachidonic Acid Treatment Against Schistosomiasis Infection in Children. 2014, Fact Sheet. Available online: https://clinicaltrials.gov/ct2/show/NCT02144389 (accessed on 10 December 2014).
118. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.; Biavatti, M.W.; Brun, R.; da Costa, F.B.; de Castro, S.L.; Ferreira, V.F.; de Lacerda, M.V.G.; et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases-Part II. Curr. Med. Chem. 2012, 19, 2176-2228.
119. De Lima, O.G.; d'Albuquerque, I.L.; Maciel, G.M.; Maciel, M.C. Antimicrobial substances of superior plants. XXVII. Isolation of plumbagin from Plumbago scandens L. Rev. Inst. Antibiot. (Recife) 1968, 8, 95-97.
120. Cichewicz, R.H.; Lim, K.-C.; McKerrow, J.H.; Nair, M.G. Kwanzoquinones A-G and other constituents of Hemerocallis fulva "Kwanzo" roots and their activity against the human pathogenic trematode Schistosoma mansoni . Tetrahedron 2002, 58, 8597-8606.
121. Magalhães, L.G.; Kapadia, G.J.; da Silva Tonuci, L.R.; Caixeta, S.C.; Parreira, N.A.; Rodrigues, V.; Da Silva Filho, A.A. In vitro schistosomicidal effects of some phloroglucinol derivatives from Dryopteris species against Schistosoma mansoni adult worms. Parasitol. Res. 2010, 106, 395-401.
122. Abdulla, M.-H.; Ruelas, D.S.; Wolff, B.; Snedecor, J.; Lim, K.-C.; Xu, F.; Renslo, A.R.; Williams, J.; McKerrow, J.H.; Caffrey, C.R. Drug discovery for schistosomiasis: Hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis. 2009, 3, e478.
123. Ramos, H.P.; Simão, M.R.; de Souza, J.M.; Magalhães, L.G.; Rodrigues, V.; Ambrósio, S.R.; Said, S. Evaluation of dihydroisocoumarins produced by the endophytic fungus Arthrinium state of Apiospora montagnei against Schistosoma mansoni. Nat. Prod. Res. 2013, 27, 2240-2243.
124. Magalhães, L.G.; Machado, C.B.; Morais, E.R.; Moreira, E.B.D.C.; Soares, C.S.; da Silva, S.H.; Da Silva Filho, A.A.; Rodrigues, V. In vitro schistosomicidal activity of curcumin against Schistosoma mansoni adult worms. Parasitol. Res. 2009, 104, 1197-1201.
125. Jana, N.R.; Dikshit, P.; Goswami, A.; Nukina, N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. 2004, 279, 11680-11685.
126. Milacic, V.; Banerjee, S.; Landis-Piwowar, K.R.; Sarkar, F.H.; Majumdar, A.P.N.; Dou, Q.P. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 2008, 68, 7283-7292.
127. Sticher, O. Natural product isolation. Nat. Prod. Rep. 2008, 25, 517-554.
128. Bucar, F.; Wube, A.; Schmid, M. Natural product isolation-how to get from biological material to pure compounds. Nat. Prod. Rep. 2013, 30, 525-545.
129. Keiser, J. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology 2010, 137, 589-603.
130. Ramirez, B.; Bickle, Q.; Yousif, F.; Fakorede, F.; Mouries, M.-A.; Nwaka, S. Schistosomes: Challenges in compound screening. Expert Opin. Drug Discov. 2007, 2, S53-S61.
131. Mansour, N.R.; Bickle, Q.D. Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl. Trop. Dis. 2010, 4, e795.
132. Paveley, R.A.; Mansour, N.R.; Hallyburton, I.; Bleicher, L.S.; Benn, A.E.; Mikic, I.; Guidi, A.; Gilbert, I.H.; Hopkins, A.L.; Bickle, Q.D. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl. Trop. Dis. 2012, 6, e1762.
133. Lee, H.; Moody-Davis, A.; Saha, U.; Suzuki, B.M.; Asarnow, D.; Chen, S.; Arkin, M.; Caffrey, C.R.; Singh, R. Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. BMC Genomics 2012, 13 (Suppl. 1), S4.
134. Paveley, R.A.; Bickle, Q.D. Automated imaging and other developments in whole-organism anthelmintic screening. Parasite Immunol. 2007, 35, 302-313.
135. Singh, S.; Carpenter, A.E.; Genovesio, A. Increasing the Content of High-Content Screening: An Overview. J. Biomol. Screen. 2014, 19, 640-650.
136. Asarnow, D.E.; Singh, R. Segmenting the etiological agent of schistosomiasis for high-content screening. IEEE Trans. Med. Imaging 2013, 32, 1007-1018.
137. Peak, E.; Chalmers, I.W.; Hoffmann, K.F. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability. PLoS Negl. Trop. Dis. 2010, 4, e759.
138. Ma, D.-L.; Chan, D.S.-H.; Leung, C.-H. Molecular docking for virtual screening of natural product databases. Chem. Sci. 2011, 2, 1656-1665.
139. Kannan, S.; Melesina, J.; Hauser, A.-T.; Chakrabarti, A.; Heimburg, T.; Schmidtkunz, K.; Walter, A.; Marek, M.; Pierce, R.J.; Romier, C.; et al. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation. J. Chem. Inf. Model. 2014, 54, 3005-3019.
140. Liu, J.; Dyer, D.; Wang, J.; Wang, S.; Du, X.; Xu, B.; Zhang, H.; Wang, X.; Hu, W. 3-Oxoacyl-ACP reductase from Schistosoma japonicum: Integrated in silico- in vitro strategy for discovering antischistosomal lead compounds. PLoS One 2013, 8, e64984.
141. Liu, J.; Dyer, D.H.; Cheng, J.; Wang, J.; Wang, S.; Yang, Z.; Wang, X.; Hu, W. Aldose reductase from Schistosoma japonicum: Crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds. Parasit. Vectors 2013, 6, 162.
142. Postigo, M.P.; Guido, R.V.C.; Oliva, G.; Castilho, M.S.; da R Pitta, I.; de Albuquerque, J.F.C.; Andricopulo, A.D. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J. Chem. Inf. Model. 2010, 50, 1693-1705.
143. Braga, R.C.; Andrade, C.H. Assessing the performance of 3D pharmacophore models in virtual screening: How good are they? Curr. Top. Med. Chem. 2013, 13, 1127-1138.
144. Valli, M.; dos Santos, R.N.; Figueira, L.D.; Nakajima, C.H.; Castro-Gamboa, I.; Andricopulo, A.D.; Bolzani, V.S. Development of a natural products database from the biodiversity of Brazil. J. Nat. Prod. 2013, 76, 439-444.
145. Dunkel, M.; Fullbeck, M.; Neumann, S.; Preissner, R. SuperNatural: A searchable database of available natural compounds. Nucleic Acids Res. 2006, 34, D678-D683.
146. Ehrman, T.M.; Barlow, D.J.; Hylands, P.J. Phytochemical informatics of traditional Chinese medicine and therapeutic relevance. J. Chem. Inf. Model. 2006, 47, 2316-2334.
147. Davis, G.D.J.; Vasanthi, A.H.R. Seaweed metabolite database (SWMD): A database of natural compounds from marine algae. Bioinformation 2011, 5, 361-364.
148. Ma, X.H.; Zhu, F.; Liu, X.; Shi, Z.; Zhang, J.X.; Yang, S.Y.; Wei, Y.Q.; Chen, Y.Z. Virtual screening methods as tools for drug lead discovery from large chemical libraries. Curr. Med. Chem. 2012, 19, 5562-5571.
149. Braga, R.C.; Alves, V.M.; Silva, A.C.; Nascimento, M.N.; Silva, F.C.; Liao, L.M.; Andrade, C.H. Virtual screening strategies in medicinal chemistry: The state of the art and current challenges. Curr. Top. Med. Chem. 2014, 14, 1899-1912.
150. Sanderson, K. Databases aim to bridge the East-West divide of drug discovery. Nat. Med. 2011, 17, 1531.
151. Chen, C.Y.-C. TCM Database@Taiwan: The world's largest traditional Chinese medicine database for drug screening in silico. PLoS One 2011, 6, e15939.
152. Dictionary of Natural Products. Available online: http://www.chemnetbase.com/ (accessed on 12 December 2014).
153. Ye, H.; Ye, L.; Kang, H.; Zhang, D.; Tao, L.; Tang, K.; Liu, X.; Zhu, R.; Liu, Q.; Chen, Y.Z.; et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 2011, 39, D1055-D1059.
154. Mangal, M.; Sagar, P.; Singh, H.; Raghava, G.P.S.; Agarwal, S.M. NPACT: Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target database. Nucleic Acids Res. 2013, 41, D1124-D1129.
155. Database of Indonesian Medicinal Plants. Available online: http://herbaldb.farmasi.ui.ac.id/ (accessed on 12 December 2014).
156. Greenpharma Natural Compound Library. Available online: http://www.greenpharma.com/products/ (accessed on 12 December 2014).
157. Yue, Y.; Chu, G.-X.; Liu, X.-S.; Tang, X.; Wang, W.; Liu, G.-J.; Yang, T.; Ling, T.-J.; Wang, X.-G.; Zhang, Z.-Z.; et al. TMDB: A literature-curated database for small molecular compounds found from tea. BMC Plant Biol . 2014, 14, 243.
158. Ashfaq, U.A.; Mumtaz, A.; Qamar, T.U.; Fatima, T. MAPS Database: Medicinal plant Activities, Phytochemical and Structural Database. Bioinformation 2013, 9, 993-995.
159. Lin, Y.-C.; Wang, C.-C.; Chen, I.-S.; Jheng, J.-L.; Li, J.-H.; Tung, C.-W. TIPdb: A database of anticancer, antiplatelet, and antituberculosis phytochemicals from indigenous plants in Taiwan. Sci. World J. 2013, 2013, doi:10.1155/2013/736386.
160. Tung, C.-W.; Lin, Y.-C.; Chang, H.-S.; Wang, C.-C.; Chen, I.-S.; Jheng, J.-L.; Li, J.-H. TIPdb-3D: the three-dimensional structure database of phytochemicals from Taiwan indigenous plants. Database (Oxford) 2014, 2014, bau055.
161. AMRI's Natural Product Library. Available online: http://www.amriglobal.com/ (accessed on 12 December 2014).
162. Wermuth, C.; Ganellin, C.; Lindberg, P.; Mitscher, L. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl. Chem. 1998, 70, 1129-1143.
163. Güner, O.; Clement, O.; Kurogi, Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: Recent advances. Curr. Med. Chem. 2004, 11, 2991-3005.
164. Richmond, N.J.; Abrams, C.A.; Wolohan, P.R.N.; Abrahamian, E.; Willett, P.; Clark, R.D. GALAHAD: 1. pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput. Aided Mol. Des. 2006, 20, 567-587.
165. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci. 1996, 36, 563-571.
166. Dixon, S.L.; Smondyrev, A.M.; Knoll, E.H.; Rao, S.N.; Shaw, D.E.; Friesner, R.A. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided. Mol. Des. 2006, 20, 647-671.
167. Cherkasov, A.; Muratov, E.N.; Fourches, D.; Varnek, A.; Baskin, I.I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y.C.; Todeschini, R.; et al. QSAR modeling: Where have you been? Where are you going to? J. Med. Chem. 2014, 57, 4977-5010.
168. Melo-Filho, C.C.; Braga, R.C.; Andrade, C.H. 3D-QSAR Approaches in Drug Design: Perspectives to Generate Reliable CoMFA Models. Curr. Comput. Aided Drug Des. 2014, 10, 148-159.
169. Neves, B.J.; Bueno, R.V.; Braga, R.C.; Andrade, C.H. Discovery of new potential hits of Plasmodium falciparum enoyl-ACP reductase through ligand- and structure-based drug design approaches. Bioorg. Med. Chem. Lett. 2013, 23, 2436-2441.
170. Bueno, R.V.; Toledo, N.R.; Neves, B.J.; Braga, R.C.; Andrade, C.H. Structural and chemical basis for enhanced affinity to a series of mycobacterial thymidine monophosphate kinase inhibitors: Fragment-based QSAR and QM/MM docking studies. J. Mol. Model. 2013, 19, 179-192.
171. Tropsha, A. Best Practices for QSAR Model Development, Validation, and Exploitation. Mol. Inf. 2010, 29, 476-488.
172. Zhang, L.; Fourches, D.; Sedykh, A.; Zhu, H.; Golbraikh, A.; Ekins, S.; Clark, J.; Connelly, M.C.; Sigal, M.; Hodges, D.; et al. Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J. Chem. Inf. Model. 2013, 53, 475-492.
173. Roy, K.; Mitra, I.; Kar, S.; Ojha, P.K.; Das, R.N.; Kabir, H. Comparative studies on some metrics for external validation of QSPR models. J. Chem. Inf. Model. 2012, 52, 396-408.
174. Roy, K.; Mitra, I. On the use of the metric rm2 as an effective tool for validation of QSAR models in computational drug design and predictive toxicology. Mini Rev. Med. Chem. 2012, 12, 491-504.
175. Roy, K.; Mitra, I.; Ojha, P.K.; Kar, S.; Das, R.N.; Kabir, H. Introduction of rm2 (rank) metric incorporating rank-order predictions as an additional tool for validation of QSAR/QSPR models. Chemom. Intell. Lab. Syst. 2012, 118, 200-210.
176. Gramatica, P. On the development and validation of QSAR models. Methods Mol. Biol. 2013, 930, 499-526.
177. Chirico, N.; Gramatica, P. Real external predictivity of QSAR models: How to evaluate it? Comparison of different validation criteria and proposal of using the concordance correlation coefficient. J. Chem. Inf. Model. 2011, 51, 2320-2335.
178. Chirico, N.; Gramatica, P. Real external predictivity of QSAR models. Part 2; New intercomparable thresholds for different validation criteria and the need for scatter plot inspection. J. Chem. Inf. Model. 2012, 52, 2044-2058.
179. Ten Brink, T.; Exner, T.E. pKa based protonation states and microspecies for protein-ligand docking. J. Comput. Aided Mol. Des. 2010, 24, 935-942.
180. Klebe, G. Virtual ligand screening: Strategies, perspectives and limitations. Drug Discov. Today 2006, 11, 580-594.
181. Lionta, E.; Spyrou, G.; Vassilatis, D.K.; Cournia, Z. Structure-based virtual screening for drug discovery: Principles, applications and recent advances. Curr. Top. Med. Chem. 2014, 14, 1923-1938.
182. McGann, M. FRED pose prediction and virtual screening accuracy. J. Chem. Inf. Model. 2011, 51, 578-596.
183. McGann, M. FRED and HYBRID docking performance on standardized datasets. J. Comput. Aided Mol. Des. 2012, 26, 897-906.
184. OEDocking, version 3.0.1; OpenEye Scientific Software, Inc.: Santa Fe, NM, USA, 2014. Available online: http://www.eyesopen.com/oedocking (accessed on 10 December 2014).
185. Toledo Warshaviak, D.; Golan, G.; Borrelli, K.W.; Zhu, K.; Kalid, O. Structure-based virtual screening approach for discovery of covalently bound ligands. J. Chem. Inf. Model. 2014, 54, 1941-1950.
186. Schellhammer, I.; Rarey, M. FlexX-Scan: Fast, structure-based virtual screening. Proteins 2004, 57, 504-517.
187. Verdonk, M.L.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Taylor, R.D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
188. Waszkowycz, B.; Clark, D.E.; Gancia, E. Outstanding challenges in protein-ligand docking and structure-based virtual screening. Wiley Interdiscip. Rev. Comput. Mol. Sci. 2011, 1, 229-259.
189. Spyrakis, F.; BidonChanal, A.; Barril, X.; Luque, F.J. Protein flexibility and ligand recognition: Challenges for molecular modeling. Curr. Top. Med. Chem. 2011, 11, 192-210.
190. Du, J.; Bleylevens, I.W.M.; Bitorina, A.V.; Wichapong, K.; Nicolaes, G.A.F. Optimization of compound ranking for structure-based virtual ligand screening using an established FRED-Surflex consensus approach. Chem. Biol. Drug Des. 2014, 83, 37-51.
191. Park, H.; Eom, J.-W.; Kim, Y.-H. Consensus scoring approach to identify the inhibitors of AMPactivated protein kinase α2 with virtual screening. J. Chem. Inf. Model. 2014, 54, 2139-2146.
192. Feher, M. Consensus scoring for protein-ligand interactions. Drug Discov. Today 2006, 11, 421-428.
193. Wolber, G.; Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 2005, 45, 160-169.
194. Steindl, T.M.; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening. J. Comput. Aided Mol. Des. 2006, 20, 703-715.
195. Caporuscio, F.; Tafi, A. Pharmacophore modelling: A forty year old approach and its modern synergies. Curr. Med. Chem. 2011, 18, 2543-2553.
196. Lauro, G.; Masullo, M.; Piacente, S.; Riccio, R.; Bifulco, G. Inverse Virtual Screening allows the discovery of the biological activity of natural compounds. Bioorg. Med. Chem. 2012, 20, 3596-3602.
197. Lauro, G.; Romano, A.; Riccio, R.; Bifulco, G. Inverse virtual screening of antitumor targets: Pilot study on a small database of natural bioactive compounds. J. Nat. Prod. 2011, 74, 1401-1407.
198. Schomburg, K.T.; Bietz, S.; Briem, H.; Henzler, A.M.; Urbaczek, S.; Rarey, M. Facing the challenges of structure-based target prediction by inverse virtual screening. J. Chem. Inf. Model. 2014, 54, 1676-1686.